Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $3.60 USD
Change Today +0.47 / 15.02%
Volume 4.4M
OGXI On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 8:10 PM 07/27/15 All times are local (Market data is delayed by at least 15 minutes).

oncogenex pharmaceutical inc (OGXI) Snapshot

Open
$3.52
Previous Close
$3.13
Day High
$3.61
Day Low
$3.22
52 Week High
07/27/15 - $3.61
52 Week Low
05/11/15 - $1.74
Market Cap
85.5M
Average Volume 10 Days
1.5M
EPS TTM
$-1.17
Shares Outstanding
23.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ONCOGENEX PHARMACEUTICAL INC (OGXI)

Related News

No related news articles were found.

oncogenex pharmaceutical inc (OGXI) Related Businessweek News

No Related Businessweek News Found

oncogenex pharmaceutical inc (OGXI) Details

OncoGenex Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapies that address treatment resistance in cancer patients. The company’s product candidates include Custirsen that is in Phase III clinical development for the treatment in men with metastatic castrate-resistant prostate cancer, as well as in patients with non-small cell lung cancer; and Apatorsen, which is in two Phase I and seven randomized Phase II trials for the treatment of bladder, lung, pancreatic, and prostate cancers. It also develops OGX-225 that is in pre-clinical development for the treatment of solid tumors. The company has a collaboration agreement with Teva Pharmaceutical Industries Ltd. to develop and commercialize Custirsen. OncoGenex Pharmaceuticals, Inc. is headquartered in Bothell, Washington.

35 Employees
Last Reported Date: 03/26/15

oncogenex pharmaceutical inc (OGXI) Top Compensated Officers

Founder, Chief Executive Officer, President, ...
Total Annual Compensation: $497.2K
Chief Financial Officer and Vice President
Total Annual Compensation: $138.3K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $413.2K
Compensation as of Fiscal Year 2014.

oncogenex pharmaceutical inc (OGXI) Key Developments

OncoGenex Announces Custirsen Phase 3 ENSPIRIT Trial Continues Following Completion of Final Futility Survival Analysis

OncoGenex Pharmaceuticals, Inc. announced that its Phase 3 ENSPIRIT trial evaluating custirsen in the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) is continuing as planned per the recommendation of an Independent Data Monitoring Committee (IDMC). This decision was based upon completion of the second and final planned interim futility analysis. Two interim analyses were originally planned to evaluate whether to stop the trial for futility. OncoGenex filed an amendment with the U.S. Food and Drug Administration amending the statistical design and analysis plan that included a more rigorous and expedient evaluation of the potential survival benefit associated with custirsen in NSCLC. Based on current enrollment, initial ENSPIRIT results could be available in the second half of 2016. Recent findings from a retrospective analysis of data from the Phase 3 SYNERGY trial showed a benefit with custirsen therapy when added to first-line docetaxel chemotherapy in men with metastatic castrate-resistant prostate cancer (CRPC) who had a poor prognosis. The analysis showed that over 40% of men in the trial had at least 2 of the 5 common risk factors for poor prognosis. In these men, the analysis found a 27% lower risk of death when custirsen was used in combination with first-line docetaxel compared to docetaxel alone. Subject to finalizing the pending protocol amendment, timing for the final analysis of the poor prognosis subpopulation in the Phase 3 AFFINITY trial is projected to occur by the end of 2015, while the final analysis for the intent-to-treat population is projected to occur in the second half of 2016.

OncoGenex Pharmaceuticals, Inc. Announces Encouraging Results from Phase II Bladder Cancer Analysis

OncoGenex Pharmaceuticals, Inc. has announced results from an exploratory analysis of the Phase II Borealis-1 trial, which showed that metastatic bladder cancer patients with poor prognostic features benefited from apatorsen 600mg added to first-line chemotherapy compared to chemotherapy alone. Patients in the trial with a Karnofsky Performance Status (KPS) of 80% or less, a common indicator of poor prognosis, experienced a 50% reduction in risk of death with the addition of apatorsen therapy (OS HR = 0.50). The trial enrolled approximately 180 patients with documented metastatic or locally inoperable transitional cell carcinoma (TCC) of the urinary tract who had not previously received chemotherapy for metastatic disease and were not candidates for potentially curative surgery or radiotherapy. Patients were randomized to receive standard chemotherapy (gemcitabine/cisplatin) in combination with apatorsen at two dose levels (600mg and 1000mg) or gemcitabine/cisplatin plus placebo. The primary endpoint of the trial was overall survival. Secondary endpoints measured disease response as well as safety of each of the two doses of apatorsen. Exploratory analysis of study results showed that survival outcome was impacted by the following prognostic risk factors: KPS, liver involvement, low hemoglobin and high alkaline phosphatase. Patients who had these poor prognostic features benefited most from 600mg apatorsen therapy. Median overall survival in the poor prognostic group was 11.9 months with 600mg apatorsen + gemcitabine/cisplatin compared to 9 months with gemcitabine/cisplatin alone (OS HR = 0.77). Importantly, 33% of patients in the trial had a KPS less than or equal to 80%, which was found to be the single most important risk factor for poor prognosis. These lower KPS, high-risk patients experienced a 50% reduction in risk of death (OS HR = 0.50) when 600mg apatorsen was added to chemotherapy. Overall treatment was well tolerated. Most common Grade greater than or equal to 3 adverse events (AEs) were neutropenia, anemia, thrombocytopenia and hypertension. Frequency of greater than or equal to 3 Grade toxicities were: 89% (GC), 93% (GC+A 600) and 95% (GC+A 1000). GC+A 1000 had a higher treatment discontinuation rate due to AEs.

OncoGenex Pharmaceuticals, Inc. - Special Call

To discuss the results from the Borealis-1 trial as well as data presented at ASCO from the SYNERGY trial of custirsen in patients with metastatic castrate-resistant prostate cancer

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OGXI:US $3.60 USD +0.47

OGXI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OGXI.
View Industry Companies
 

Industry Analysis

OGXI

Industry Average

Valuation OGXI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.2x
Price/Book 2.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONCOGENEX PHARMACEUTICAL INC, please visit www.oncogenex.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.